Cetera Investment Advisers
BBC icon

Cetera Investment Advisers’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Cetera Investment Advisers’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-8,259
Closed -$377K – 1858
2021
Q3 		$377K Sell
8,259
-8,163
-50% -$382K 0.01% 1300
2021
Q2 		$820K Buy
16,422
+333
+2% +$16.3K 0.01% 854
2021
Q1 		$827K Buy
16,089
+156
+1% +$8.53K 0.02% 749
2020
Q4 		$790K Buy
15,933
+1,130
+8% +$50.8K 0.02% 761
2020
Q3 		$577K Buy
+14,803
New +$603K 0.05% 348

Other funds holding BBC

Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
FTUS
Flow Traders U.S. New York $3.16B AUM 19.52% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $6.48B AUM 18.23% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return

Cetera Investment Advisers's BBC Position: Q4 2021 in Review

Cetera Investment Advisers sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q4 2021, closing a stake of 8,259 shares — an estimated $377K sold.

Cetera Investment Advisers first reported a position in BBC in Q3 2020 and held it in 5 quarters. The position peaked at $827K in Q1 2021. 19 funds tracked by Wall St. Rank hold BBC as of Q4 2021.

  • Cetera Investment Advisers reported no remaining Virtus Biotech Clinical Trials ETF position as of Q4 2021 after selling out during the quarter.
  • Cetera Investment Advisers sold 8,259 Virtus Biotech Clinical Trials ETF shares in Q4 2021, an estimated $377K.
  • Cetera Investment Advisers first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2020 and held it in 5 quarters.
  • Cetera Investment Advisers's Virtus Biotech Clinical Trials ETF position peaked at $827K in Q1 2021.
  • 19 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q4 2021.

Based on Cetera Investment Advisers's 13F filing for Q4 2021, filed 14 Feb 2022.